Alzheimer's Disease trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Alzheimer's Disease. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month6 studies across 5 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| IGC | IGC Pharma, LLC | Clinical Trial on Agitation in Alzheimer's DementiaNCT05543681Agitation | Phase 2 | Recruiting | Aug 2026 | ≤ 11 d | 2026-05-20 |
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | A Study to Compare Two Different Sleep Tests in Participants With No Symptoms or Early Symptoms of Alzheimer's DiseaseNCT07485153observationalPercentage of Agreement between Participants with the Same Results in Sleep Staging Using EEG and Sleep Study | — | Not yet recruiting | Sep 2026 | ≤ 41 d | 2026-03-20 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ABOS | Acumen Pharmaceuticals | A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)NCT06335173Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score | Phase 2 | Active, not recruiting | Oct 2026 | ≤ 72 d | 2025-10-27 |
December 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| 4523.T | Eisai Inc. | A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's DiseaseNCT06602258Change From Baseline in CSF MTBR-tau-243 at 6 Months | Phase 2 | Active, not recruiting | 2026-12-03 | in 105 d | 2026-02-11 |
| 4523.T | Eisai Inc. | A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's DiseaseNCT07723950observationalPositive Predictive Value (PPV) of algorithms to identify intracerebral hemorrhage >1 cm in diameter | — | Not yet recruiting | 2026-12-31 | in 133 d | 2026-07-23 |
| PMN | ProMis Neurosciences, Inc | PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)NCT06750432Safety and tolerability of PMN310 following repeat intravenous infusions of PMN310 | Phase 1 | Active, not recruiting | Dec 2026 | ≤ 133 d | 2026-07-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Alzheimer's Disease
most recently updated first358 studies match. Showing the first 100 of 358 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)NCT06937229Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 3 | Recruiting | Drug: KarXT, KarX-EC | Alzheimer Disease, Agitation | 650 | 2025-12-02 | 2029-06-22 | in 1,037 d | 2026-08-19 |
| NVO | Novo Nordisk A/S | — | A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's DiseaseNCT05891496results2026-02-24Change in Gene Expression Assessed by Single-cell Ribonucleic Acid Sequencing (scRNAseq) (Cells in Cerebrospinal Fluid [CSF]) | Phase 3 | Completed | Drug: Semaglutide, Placebo | Alzheimers Disease | 23 | 2023-06-20 | 2024-08-19actual | — | 2026-08-18 |
| 4523.T | Eisai Inc. | $8.7B | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD)NCT07768592Part A (Core Trial): Change from Baseline in [11C]MK-6884 Positron Emission Tomography (PET) Using Non-Displaceable Binding Potential (BPND) at 14 Days | Phase 1 | Not yet recruiting | Drug: E2511, Donepezil | Alzheimers Disease | 32 | 2026-10-15 | 2030-05-06 | in 1,355 d | 2026-08-17 |
| ALNY | Alnylam Pharmaceuticals | $30.6B | A Study to Evaluate ALN-5288 in Patients With Alzheimer's DiseaseNCT07214727Frequency of Adverse Events (AEs) | Phase 1 | Recruiting | Drug: ALN-5288, Placebo | Alzheimer's Disease | 50 | 2025-10-15 | 2030-03-06 | in 1,294 d | 2026-08-14 |
| ABBV | AbbVie | $457.5B | A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's DiseaseNCT07599670Percentage of Participants Experiencing Adverse Events (AEs) | Phase 1/2 | Recruiting | Drug: ABBV-1758, Placebo for ABBV-1758, ABBV-1758, Placebo for ABBV-1758 | Alzheimer's Disease | 210 | 2026-05-15 | Apr 2030 | ≤ 1,349 d | 2026-08-14 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease AgitationNCT05557409results2026-08-13Cohen-Mansfield Agitation Inventory (CMAI) | Phase 3 | Completed | Drug: AXS-05, Placebo | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation | 408 | 2022-09-06 | 2024-11-21actual | — | 2026-08-13 |
| 4523.T | Eisai Limited | $8.7B | A Post Authorization Registry Study of Participants Treated With LEQEMBINCT07762092observationalIncidence and Severity of Known AEs | — | Not yet recruiting | Other: No Intervention | Alzheimers Disease | 400 | 2026-07-31 | 2036-04-01 | in 3,512 d | 2026-08-13 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)NCT06976203Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11) | Phase 3 | Recruiting | Drug: KarXT, KarX-EC · Other: Placebo | Alzheimer's Disease | 586 | 2025-07-21 | 2028-09-11 | in 753 d | 2026-08-12 |
| BMY | Bristol-Myers Squibb | $134.9B | A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)NCT07011732Change from baseline on the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association (CMAI-IPA) Total Score at Week 14 | Phase 3 | Recruiting | Drug: Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo | Alzheimer Disease | 426 | 2025-07-10 | 2028-11-24 | in 827 d | 2026-08-11 |
| DNLI | Denali Therapeutics Inc. | $3.9B | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's DiseaseNCT07758595Part A: Incidence and severity of treatment-emergent averse events (TEAEs) | Phase 1 | Not yet recruiting | Drug: DNL921, Placebo | Alzheimer's Disease, Healthy Participants | 178 | Aug 2026 | Apr 2030 | ≤ 1,349 d | 2026-08-11 |
| CGTX | Cognition Therapeutics | $93M | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's DiseaseNCT05531656Change from baseline in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) scale. | Phase 2 | Active, not recruiting | Drug: CT1812, Placebo | Early Alzheimer's Disease | 540 | 2023-06-28 | 2027-05-31 | in 284 d | 2026-08-10 |
| SNY | Sanofi | — | A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's DiseaseNCT07688213Part A and optional dose 2 cohort: change from baseline to Week 48 in plasma p-tau217 | Phase 2 | Recruiting | Drug: SAR448851, Placebo | Dementia, Alzheimer's Type, Alzheimer's Disease | 160 | 2026-07-28 | 2029-07-31 | in 1,076 d | 2026-08-10 |
| MPLT | MapLight Therapeutics | $477M | An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease PsychosisNCT07459660To assess the safety and tolerability of long-term ML-007C-MA administration in participants with hallucinations and delusions associated with AD | Phase 2 | Enrolling by invitation | Drug: ML-007C-MA | Psychosis Associated With Alzheimer's Disease | 210 | 2026-03-25 | Mar 2029 | ≤ 954 d | 2026-08-07 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3439539 in Participants With Alzheimer's DiseaseNCT07598370Change from Baseline in Cerebrospinal Fluid (CSF) Neurofilament Light Chain (NfL) | Phase 1 | Recruiting | Drug: LY3439539 | Alzheimer Disease | 30 | 2026-05-21 | Aug 2027 | ≤ 376 d | 2026-08-07 |
| LLY | Eli Lilly and Company | $1.15T | Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's DiseaseNCT07571161Time to Clinical Progression as Measured by Clinical Dementia Rating-Global Score (CDR-GS) | Phase 3 | Recruiting | Drug: Donanemab, Placebo | Alzheimer Disease | 140 | 2026-04-30 | Apr 2030 | ≤ 1,349 d | 2026-08-06 |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.2B | ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension StudyNCT06194799Treatment-emergent adverse events | Phase 3 | Enrolling by invitation | Drug: ACP-204 | Alzheimer's Disease Psychosis | 752 | 2024-04-23 | Apr 2029 | ≤ 984 d | 2026-08-05 |
| MPLT | MapLight Therapeutics | $477M | A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisNCT06887192Change from Baseline to End of Treatment in the Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C H+D) score | Phase 2 | Recruiting | Drug: ML-007C-MA, Placebo | Psychosis Associated With Alzheimer's Disease | 300 | 2025-08-15 | Dec 2027 | ≤ 498 d | 2026-07-29 |
| BMY | Bristol-Myers Squibb | $134.9B | A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseaseNCT07011745Change from baseline on the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association (CMAI-IPA) total score at Week 14 | Phase 3 | Recruiting | Drug: Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo | Alzheimer's Disease | 426 | 2025-07-16 | 2028-11-03 | in 806 d | 2026-07-29 |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.2B | ACP-204 in Adults With Alzheimer's Disease PsychosisNCT06159673Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales (SAPS-H+D) total score change from baseline (Substudies 1, 2A, 2B) | Phase 2/3 | Recruiting | Drug: ACP-204, Placebo | Alzheimer's Disease Psychosis | 1,074 | 2023-11-14 | Jan 2028 | ≤ 529 d | 2026-07-24 |
| 4523.T | Eisai Inc. | $8.7B | A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's DiseaseNCT07723950observationalPositive Predictive Value (PPV) of algorithms to identify intracerebral hemorrhage >1 cm in diameter | — | Not yet recruiting | Other: No intervention | Alzheimer's Disease | 600 | 2026-07-30 | 2026-12-31 | in 133 d | 2026-07-23 |
| ACOG | Alpha Cognition, Inc | $187M | A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)NCT07633470Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 4 | Recruiting | Drug: Zunveyl® | Alzheimer Disease | 150 | 2026-05-20 | Apr 2027 | ≤ 253 d | 2026-07-20 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)NCT05508789Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) | Phase 3 | Active, not recruiting | Drug: Donanemab, Placebo | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 1,500 | 2022-10-10 | May 2028 | ≤ 650 d | 2026-07-16 |
| PMN | ProMis Neurosciences, Inc | $134M | PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)NCT06750432Safety and tolerability of PMN310 following repeat intravenous infusions of PMN310 | Phase 1 | Active, not recruiting | Drug: PMN310, Placebo | Alzheimer Disease, Early Onset | 144 | 2024-12-13 | Dec 2026 | ≤ 133 d | 2026-07-13 |
| NVO | Novo Nordisk A/S | — | A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)NCT04777396Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score | Phase 3 | Completed | Drug: Semagludtide, Placebo (semaglutide) | Early Alzheimer's Disease | 1,840 | 2021-05-18 | 2025-09-16actual | — | 2026-07-07 |
| LLY | Eli Lilly and Company | $1.15T | Epidemiology and Biomarker Study in Alzheimer's DiseaseNCT07142954Time to Cognitive Worsening Within Cohorts as Measured by Cognitive Composite or Any of the Individual Composite Components | Phase 3 | Recruiting | Other: P-tau217 Test | Alzheimer Disease | 3,400 | 2025-08-25 | Jul 2033 | ≤ 2,537 d | 2026-07-07 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).NCT07602582Change from Baseline as Measured by Clinical Dementia Rating - Sum of Boxes (CDR-SB) | Phase 3 | Recruiting | Drug: Donanemab, Placebo | Alzheimer Disease, Dementia, Plaque, Amyloid | 550 | 2026-05-22 | Sep 2029 | ≤ 1,137 d | 2026-07-07 |
| DNLI | Denali Therapeutics Inc. | $3.9B | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's DiseaseNCT07328451Incidence and severity of treatment-emergent adverse events (TEAEs) throughout the double-blind period | Phase 1 | Recruiting | Drug: DNL628, Placebo | Alzheimer Disease, Early Onset | 68 | 2026-01-30 | Feb 2027 | ≤ 192 d | 2026-07-01 |
| BIIB | Biogen | $31.4B | A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of AgeNCT05399888Dose response in Change From Baseline to Week 76 on the CDR-SB | Phase 2 | Active, not recruiting | Drug: Diranersen, Diranersen-matching placebo | Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia | 416 | 2022-08-24 | 2026-03-11actual | — | 2026-06-30 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)NCT06947941Change From Baseline in Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C: H+D) Score | Phase 3 | Recruiting | Drug: KarXT, KarX-EC, KarXT + KarX-EC Arm Matching Placebo | Alzheimer Disease, Psychosis | 325 | 2026-03-25 | 2028-02-21 | in 550 d | 2026-06-30 |
| INMB | Inmune Bio, Inc. | $59M | A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of InflammationNCT05318976results2026-06-29Change in Early and Mild Alzheimer's Cognitive Composite (EMACC) | Phase 2 | Completed | Drug: XPro1595, Placebo | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders, Mild Cognitive Impairment | 207 | 2022-02-28 | 2025-05-12actual | — | 2026-06-29 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseNCT06976216Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11) | Phase 3 | Recruiting | Drug: KarXT, KarX-EC · Other: Placebo | Alzheimer's Disease | 586 | 2025-07-14 | 2028-09-11 | in 753 d | 2026-06-26 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension StudyNCT06736509results2026-06-25Long-Term Safety | Phase 3 | Terminatedsponsor's stated reason: Study AXS-05-AD-305 was terminated due to completion of overall program objectives. | Drug: AXS-05 (dextromethorphan-bupropion) | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor | 139 | 2024-11-21 | 2025-02-17actual | — | 2026-06-25 |
| ARWR | Arrowhead Pharmaceuticals | $12.4B | Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's DiseaseNCT07221344Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Over Time | Phase 1/2 | Recruiting | Drug: ARO-MAPT-SC, Placebo | Alzheimer Disease, Alzheimer Disease, Early Onset | 112 | 2025-11-18 | Jun 2027 | ≤ 314 d | 2026-06-23 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)NCT05738486results2025-11-14Percentage of Participants With Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E) | Phase 3 | Active, not recruiting | Drug: Donanemab, Placebo, Dexamethasone | Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 1,175 | 2023-02-28 | 2024-05-16actual | — | 2026-06-18 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Mevidalen (LY3154207) in Participants With Alzheimer's DiseaseNCT06538116Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) | Phase 2 | Completed | Drug: Mevidalen, Placebo | Alzheimer Disease | 304 | 2024-08-26 | 2026-05-01actual | — | 2026-06-18 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's DiseaseNCT05063539results2025-07-28Change From Baseline to End Time Point in Integrated Alzheimer's Disease Rating Scale (iADRS) (Intermediate (Low-medium) Tau Population) | Phase 2 | Completed | Drug: LY3372689, LY3372689, Placebo | Alzheimer Disease | 327 | 2021-09-16 | 2024-07-09actual | — | 2026-06-12 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)NCT06657768Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Discontinuations due to Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Recruiting | Drug: LY4006895, Placebo | Alzheimer Disease, Healthy | 128 | 2024-10-29 | Jul 2027 | ≤ 345 d | 2026-06-04 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)NCT05463731Percentage of Participants Who Reach Amyloid Plaque Clearance on Amyloid PET Scan for Remternetug versus Placebo | Phase 3 | Completed | Drug: Remternetug (IV), Remternetug (SC), Placebo | Alzheimer's Disease | 1,667 | 2022-08-01 | 2024-04-24actual | — | 2026-05-22 |
| NMRA | Neumora Therapeutics, Inc. | $286M | Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's DiseaseNCT06546995Part A: Safety and Tolerability Assessments Based on Treatment Emergent Adverse Events (TEAEs) and Validated Clinical Scales | Phase 1 | Completed | Drug: NMRA-323511, Placebo | Alzheimer's Disease, Healthy Elderly | 87 | 2024-07-09 | 2025-11-19actual | — | 2026-05-22 |
| IGC | IGC Pharma, LLC | $29M | Clinical Trial on Agitation in Alzheimer's DementiaNCT05543681Agitation | Phase 2 | Recruiting | Drug: IGC-AD1-Active, IGC-AD1-Placebo | Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS, Aggression | 164 | 2022-10-11 | Aug 2026 | ≤ 11 d | 2026-05-20 |
| LLY | Eli Lilly and Company | $1.15T | A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's DiseaseNCT06297590Part A: Number of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration | Phase 1 | Recruiting | Drug: LY3954068, Placebo, Flortaucipir F18 | Alzheimer Disease | 48 | 2024-08-15 | Feb 2027 | ≤ 192 d | 2026-04-20 |
| 4523.T | Eisai Inc. | $8.7B | A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseaseNCT03887455Core Study: Change from Baseline in the CDR-SB at 18 Months | Phase 3 | Active, not recruiting | Drug: Lecanemab IV, Placebo, Lecanemab SC | Early Alzheimer's Disease | 1,906 | 2019-03-27 | 2029-06-30 | in 1,045 d | 2026-04-07 |
| LLY | Eli Lilly and Company | $1.15T | A Study to Compare Two Different Sleep Tests in Participants With No Symptoms or Early Symptoms of Alzheimer's DiseaseNCT07485153observationalPercentage of Agreement between Participants with the Same Results in Sleep Staging Using EEG and Sleep Study | — | Not yet recruiting | Device: Mobile EEG, Activity Monitor, Sleep Study | Alzheimer's Disease, Early Alzheimer's Disease, Memory Problems | 35 | Mar 2026 | Sep 2026 | ≤ 41 d | 2026-03-20 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)NCT03367403results2022-02-15Change From Baseline in the Integrated Alzheimer's Disease Rating Scale (iADRS) Score | Phase 2 | Completed | Drug: Donanemab, Placebo, LY3202626 | Alzheimer Disease | 272 | 2017-12-18 | 2020-12-04actual | — | 2026-03-19 |
| 4523.T | Eisai Limited | $8.7B | A Community-Based Screening Program to Identify Participants at High Risk for Amyloid PathologyNCT06043700observationalNumber of Participants With Low, Medium, and High Amyloid Pathology | — | Active, not recruiting | Other: No Intervention | Alzheimer's Disease | 2,000 | 2023-09-12 | 2028-03-31 | in 589 d | 2026-03-05 |
| 4523.T | Eisai Inc. | $8.7B | A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's DiseaseNCT01767311results2026-03-04Core Study Phase: Change From Baseline in Alzheimer's Disease Composite Score (ADCOMS) at Month 12 | Phase 2 | Completed | Drug: Lecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg, Placebo, Lecanemab 10 mg/kg | Alzheimer's Disease | 856 | 2012-12-20 | 2024-12-10actual | — | 2026-03-04 |
| INMB | Inmune Bio, Inc. | $59M | An Open-Label Extension of XPro1595 in Patients With Alzheimer's DiseaseNCT05522387Number of participants who experience adverse events and serious adverse events | Phase 2 | Terminatedsponsor's stated reason: Sponsor resource allocation | Drug: XPro1595 | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 11 | 2023-02-21 | 2024-06-05actual | — | 2026-02-27 |
| ALEC | Alector Inc. | $247M | A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's DiseaseNCT05744401results2026-02-25Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). | Phase 2 | Terminatedsponsor's stated reason: Parent study failed to meet the primary endpoint and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints. | Drug: AL002 | Alzheimer's Disease | 197 | 2023-01-04 | 2025-01-31actual | — | 2026-02-25 |
| IONS | Ionis Pharmaceuticals, Inc. | $9.9B | Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)NCT06673069Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision to terminate study early. Decision not based on safety concerns. | Drug: ION269 | Alzheimer Disease, Down Syndrome | 1 | 2024-12-20 | 2025-12-03actual | — | 2026-02-20 |
| 4523.T | Eisai Inc. | $8.7B | A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's DiseaseNCT06602258Change From Baseline in CSF MTBR-tau-243 at 6 Months | Phase 2 | Active, not recruiting | Drug: E2814, Lecanemab, Placebo | Alzheimer's Disease | 105 | 2024-09-30 | 2026-12-03 | in 105 d | 2026-02-11 |
| 4523.T | Eisai Co., Ltd. | $8.7B | A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With LecanemabNCT06322667observationalNumber of Participants With Amyloid Related Imaging Abnormality-Oedema/Effusion (ARIA-E) and Amyloid Related Imaging Abnormality-Microhemorrhage and Hemosiderin Deposit, and Cerebellar Microhaemorrhage (ARIA-H) | — | Recruiting | Other: No Intervention | Alzheimer's Disease | 5,000 | 2024-02-14 | 2027-12-31 | in 498 d | 2026-01-23 |
| LLY | Eli Lilly and Company | $1.15T | A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)NCT05026866Time to Clinical Progression of Composite Endpoint as Measured by Clinical Dementia Rating (CDR) in the Primary Study Population (Baseline CDR-Global Score [GS 0]) | Phase 3 | Active, not recruiting | Drug: Donanemab, Placebo | Alzheimer Disease | 2,996 | 2021-08-27 | Nov 2027 | ≤ 467 d | 2026-01-21 |
| ABBV | AbbVie | $457.5B | A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's DiseaseNCT05291234Number of Participants Experiencing Adverse Events (AEs) | Phase 2 | Completed | Drug: ABBV-916, Placebo | Alzheimer's Disease (AD) | 106 | 2022-08-15 | 2025-11-19actual | — | 2025-12-10 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease AgitationNCT04947553Long-term Safety | Phase 3 | Completed | Drug: AXS-05 (dextromethorphan-bupropion), Placebo | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor | 456 | 2021-06-17 | 2024-12-03actual | — | 2025-12-08 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)NCT06653153Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate Scale (CDR) | Phase 3 | Active, not recruiting | Drug: Remternetug, Placebo | Alzheimer's Disease | 1,400 | 2024-10-24 | Apr 2029 | ≤ 984 d | 2025-11-20 |
| ALEC | Alector Inc. | $247M | A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's DiseaseNCT04592874results2025-10-29Disease Progression as Measured by the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score | Phase 2 | Completed | Drug: AL002, Placebo | Alzheimer Disease | 356 | 2021-01-22 | 2024-08-19actual | — | 2025-10-29 |
| ABOS | Acumen Pharmaceuticals | $192M | A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)NCT06335173Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score | Phase 2 | Active, not recruiting | Drug: sabirnetug, Placebo | Alzheimer Disease | 542 | 2024-02-29 | Oct 2026 | ≤ 72 d | 2025-10-27 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)NCT02951598observationalMean Economic Cost Associated with Amyloid Positive AD | — | Active, not recruiting | Drug: Florbetapir F 18 PET Scan | Alzheimer Disease, Mild Cognitive Impairment | 1,400 | 2016-10-29 | 2021-01-30actual | — | 2025-10-24 |
| LXEO | Lexeo Therapeutics | $404M | Gene Therapy for APOE4 Homozygote of Alzheimer's DiseaseNCT03634007Proportion of participants with treatment-emergent adverse events and serious adverse events | Phase 1/2 | Completed | Biological: LX1001 | Alzheimer Disease, Early Onset Alzheimer Disease | 15 | 2019-11-06 | 2024-11-07actual | — | 2025-10-20 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's DiseaseNCT05771428results2025-10-15Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) Score at Week 12 | Phase 2 | Completed | Drug: ABBV-552, Placebo for ABBV-552 | Alzheimer's Disease (AD) | 263 | 2023-06-05 | 2024-08-06actual | — | 2025-10-15 |
| LLY | Eli Lilly and Company | $1.15T | A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's DiseaseNCT06566170observationalTime to First Increase in Dependence Level Above Baseline (as derived from the Dependence Scale [DS]) | — | Recruiting | Drug: Donanemab, Usual Care | Alzheimer Disease | 6,250 | 2024-10-07 | Feb 2033 | ≤ 2,384 d | 2025-10-09 |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.8B | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)NCT04602624results2024-10-10Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Phase 2 | Completed | Drug: SAGE-718 | Alzheimer Disease, Cognitive Dysfunction, Mild Dementia | 26 | 2020-12-07 | 2021-09-28actual | — | 2025-09-15 |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.8B | A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)NCT05619692results2025-06-18Change From Baseline in the Wechsler Adult Intelligence Scale-IV (WAIS-IV) Coding Test Score | Phase 2 | Completed | Drug: SAGE-718, SAGE-718-matching Placebo | Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease | 174 | 2022-11-29 | 2024-06-05actual | — | 2025-09-15 |
| ALZN | Alzamend Neuro, Inc. | $8M | Study in Subjects With Mild-to-Moderate Alzheimer's DementiaNCT05834296TEAEs | Phase 1/2 | Active, not recruiting | Biological: ALZN002 (autologous DCs pulsed with E22W mutant peptide). · Drug: Placebo | Alzheimer Disease | 30 | 2023-07-05 | 2028-03-03 | in 561 d | 2025-09-02 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)NCT04437511results2024-05-20Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population) | Phase 3 | Active, not recruiting | Drug: Donanemab, Placebo | Alzheimer Disease | 1,736 | 2020-06-19 | 2023-04-14actual | — | 2025-08-29 |
| CGTX | Cognition Therapeutics | $93M | A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.NCT03507790results2025-08-11Number of Study Participants With at Least One Mild, Moderate, or Severe Treatment Emergent Adverse Events (TEAEs) | Phase 2 | Completed | Drug: CT1812, Placebo | Mild to Moderate Alzheimer's Disease | 153 | 2018-10-10 | 2024-05-29actual | — | 2025-08-11 |
| BMY | Bristol-Myers Squibb | $134.9B | Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's DiseaseNCT06268886Change from baseline in brain tau deposition as measured by tau positron emission tomography (PET) | Phase 2 | Active, not recruiting | Drug: BMS-986446 · Other: Placebo | Alzheimer Disease, Early Onset | 310 | 2024-03-20 | 2027-03-18 | in 210 d | 2025-07-24 |
| ABBV | AbbVie | $457.5B | A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy ParticipantsNCT06406348Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Phase 1 | Completed | Drug: ALIA-1758 · Other: Placebo | Alzheimer Disease | 53 | 2024-05-09 | 2025-04-22actual | — | 2025-07-17 |
| LXEO | Lexeo Therapeutics | $404M | Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's DiseaseNCT05400330Incidence of treatment emergent adverse events | Phase 1 | Active, not recruiting | Biological: LX1001 | Alzheimer Disease | 10 | 2023-05-08 | Nov 2028 | ≤ 833 d | 2025-07-01 |
| LLY | Eli Lilly and Company | $1.15T | A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)NCT04640077results2025-06-13Part A: Intraclass Correlation Between On-Site and Video Teleconference (VTC) Assessments | Phase 2 | Completed | Other: No Intervention · Drug: donanemab | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Cognitive Impairment | 95 | 2020-11-23 | 2024-02-27actual | — | 2025-06-13 |
| 4523.T | Eisai Inc. | $8.7B | A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's DiseaseNCT04971733results2025-06-10Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs | Phase 1/2 | Completed | Drug: E2814 | Alzheimer Disease | 8 | 2021-06-28 | 2024-05-24actual | — | 2025-06-10 |
| ALZN | Alzamend Neuro, Inc. | $8M | Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult SubjectsNCT05363293results2025-05-14Number of Participants With Serious AEs, TEAEs That Lead to Premature Discontinuation, Abnormal Laboratory Test Results, Abnormal ECG Readings. | Phase 1/2 | Completed | Drug: AL001 · Other: Placebo | Alzheimer's Disease, Healthy Non-elderly and Elderly Adults | 65 | 2022-05-04 | 2023-04-14actual | — | 2025-05-14 |
| ABBV | AbbVie | $457.5B | A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's DiseaseNCT05644977Part A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Completed | Drug: Emraclidine, Placebo | Healthy Participants, Alzheimer's Disease Dementia | 17 | 2022-12-02 | 2025-04-14actual | — | 2025-05-02 |
| ANVS | Annovis Bio Inc. | $77M | A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate ADNCT05686044results2025-04-29Change From Baseline to Week 12 in ADAS-Cog11 | Phase 2/3 | Completed | Drug: Buntanetap/Posiphen, Placebo | Alzheimer Disease | 351 | 2023-04-01 | 2024-02-13actual | — | 2025-04-29 |
| BIIB | Biogen | $31.4B | A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's DiseaseNCT05310071results2025-04-23Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score at Week 78 | Phase 3 | Terminatedsponsor's stated reason: Sponsor's Decision | Drug: Aducanumab, Placebo | Alzheimer's Disease | 1,027 | 2022-06-02 | 2024-08-12actual | — | 2025-04-23 |
| IONS | Ionis Pharmaceuticals, Inc. | $9.9B | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's DiseaseNCT03186989results2025-04-08Part 1: Number of Participants With Adverse Events That Are Related to Treatment With ISIS 814907 | Phase 1 | Completed | Drug: IONIS MAPTRx · Other: Placebo | Mild Alzheimer's Disease | 46 | 2017-10-12 | 2022-05-12actual | — | 2025-04-08 |
| LONA | LeonaBio | $73M | ATH-1017 for Treatment of Mild to Moderate Alzheimer's DiseaseNCT04488419results2025-04-04Global Statistical Test (GST) Score | Phase 2/3 | Completed | Drug: ATH-1017, Placebo | Alzheimer Disease, Dementia of Alzheimer Type | 554 | 2020-09-28 | 2024-07-15actual | — | 2025-04-04 |
| LONA | LeonaBio | $73M | Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's DiseaseNCT04886063results2025-04-01Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Phase 2/3 | Terminatedsponsor's stated reason: ATH-1017-AD-0203 was terminated after the Ph2/3 parent trial (LIFT-AD; NCT04488419) did not meet its primary endpoint, the GST score. | Drug: ATH-1017 | Alzheimer Disease | 423 | 2021-06-30 | 2024-10-23actual | — | 2025-04-01 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy ParticipantsNCT04451408Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Completed | Drug: LY3372993, Placebo | Alzheimer Disease, Healthy | 139 | 2020-07-07 | 2024-11-18actual | — | 2025-03-28 |
| AMLX | Amylyx Pharmaceuticals Inc. | $3.9B | Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's DiseaseNCT03533257results2025-03-07Number of Participants With Treatment-Emergent Adverse Event (TEAEs) | Phase 2 | Completed | Drug: AMX0035, Placebo | Alzheimer Disease | 95 | 2018-09-14 | 2020-10-22actual | — | 2025-03-07 |
| BIIB | Biogen | $31.4B | A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205NCT04241068results2025-02-21Core Treatment Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs | Phase 3 | Terminatedsponsor's stated reason: Sponsor's Decision | Drug: Aducanumab | Alzheimer's Disease | 1,696 | 2020-03-02 | 2024-07-22actual | — | 2025-02-21 |
| CGTX | Cognition Therapeutics | $93M | Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEGNCT04735536results2024-11-29Number of TEAEs, Related TEAEs, SAEs, and Related SAEs | Phase 2 | Completed | Drug: CT1812 · Other: Placebo | Alzheimer Disease | 16 | 2020-07-09 | 2023-04-26actual | — | 2024-11-29 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)NCT05108922results2023-11-02Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus Aducanumab | Phase 3 | Completed | Drug: Donanemab, Aducanumab | Mild Cognitive Impairment (MCI), Alzheimer Disease | 148 | 2021-11-16 | 2022-09-09actual | — | 2024-11-29 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of DonepezilNCT01406145Number and percentage of subjects with adverse events | Phase 1 | Completed | Drug: ASP0777, Placebo | Alzheimer's Disease | 60 | 2011-06-16 | 2011-11-04actual | — | 2024-10-30 |
| ABOS | Acumen Pharmaceuticals | $192M | A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy ParticipantsNCT06511570Estimate blood levels of sabirnetug (ACU193) | Phase 1 | Completed | Drug: sabirnetug (ACU193) · Combination product: Sabirnetug + rHuPH20 | Alzheimer Disease | 28 | 2024-06-25 | 2024-09-17actual | — | 2024-10-18 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or ADNCT02624778results2024-10-08Change From Baseline in Florbetapir Positron Emission Tomography (PET) Scan Standard Uptake Value Ratio (SUVr) | Phase 1 | Completed | Biological: LY3002813 · Drug: Placebo | Alzheimer Disease | 61 | 2015-12-22 | 2019-08-28actual | — | 2024-10-08 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3002813 in Participants With Alzheimer's DiseaseNCT01837641results2024-10-04Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Completed | Biological: LY3002813-IV, LY3002813-SC · Drug: Placebo-IV | Alzheimer Disease | 63 | 2013-05-03 | 2016-08-24actual | — | 2024-10-04 |
| VCNX | Vaccinex Inc. | $3M | SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)NCT04381468Number of subjects with treatment emergent adverse events (TEAEs) | Phase 1/2 | Completed | Drug: Pepinemab, Placebo | Alzheimer Disease | 50 | 2021-07-22 | 2024-06-05actual | — | 2024-08-22 |
| AVXL | Anavex Life Sciences Corp. | $297M | OLE of Phase 2b/3 Study ANAVEX2-73-AD-004NCT04314934Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 | Phase 2/3 | Completed | Drug: ANAVEX2-73 | Alzheimer Disease | 300 | 2019-10-10 | 2024-06-14actual | — | 2024-08-12 |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.4B | A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's DiseaseNCT02127476Number of Participants with Adverse Events as a Measure of Safety and Tolerability | Phase 1 | Completed | Drug: KHK6640, Matching Placebo | Alzheimer's Disease | 57 | Jul 2014 | May 2017actual | — | 2024-06-17 |
| PFE | Pfizer | $155.3B | A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's DiseaseNCT00945672results2024-04-19Number of Participants With Treatment-emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) | Phase 2 | Completed | Biological: PF-04360365 10 mg/kg, PF-04360365 7.5 mg/kg · Drug: placebo | Alzheimer's Disease | 36 | 2009-08-06 | 2011-06-01actual | — | 2024-04-19 |
| LGVN | Longeveron Inc. | $14M | Lomecel-B Effects on Alzheimer's DiseaseNCT05233774Primary Endpoint 1: Safety - SAEs and AEs | Phase 2 | Completed | Drug: Allogeneic MSC · Other: Placebo | Mild Alzheimer's Disease | 50 | 2021-12-28 | 2023-09-29actual | — | 2024-02-20 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | Assessing Clinical Outcomes in Alzheimer's Disease AgitationNCT04797715Time from randomization to relapse of agitation symptoms | Phase 3 | Completed | Drug: AXS-05, Placebo | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor | 178 | 2020-12-31 | 2022-11-21actual | — | 2023-11-29 |
| BIVI | BioVie Inc. | $7M | A Phase 3 Study of NE3107 in Probable Alzheimer's DiseaseNCT04669028Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) | Phase 3 | Completed | Drug: NE3107, Placebo | Alzheimer Disease | 439 | 2021-08-05 | 2023-09-30actual | — | 2023-11-21 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)NCT02754830results2023-09-21Number of Participants With One or More Serious Adverse Event(s) (SAEs) to be Related to Study Drug Administration | Phase 1 | Completed | Drug: LY3303560 - IV, Saline Solution - IV, LY3303560 - SC | Alzheimer's Disease | 72 | 2016-04-25 | 2018-07-10actual | — | 2023-10-13 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's DiseaseNCT03019536results2023-10-10Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Completed | Drug: LY3303560 - IV, Placebo - IV, Florbetapir F 18, Flortaucipir F18 | Alzheimer Disease | 22 | 2017-01-31 | 2019-06-05actual | — | 2023-10-10 |
| INMB | Inmune Bio, Inc. | $59M | Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of InflammationNCT05321498Change in Early and Mild Alzheimer's Cognitive Composite (EMACC) | Phase 2 | Withdrawnsponsor's stated reason: MCI patients will now be enrolled in the XPro1595-AD-02 study. | Drug: XPro1595, Placebo | Mild Cognitive Impairment (MCI), Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Mental Disorders | 0 | Jun 2023 | 2023-10-26 | — | 2023-09-28 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | Addressing Dementia Via Agitation-Centered EvaluationNCT03226522results2023-09-13Change in CMAI Total Score | Phase 2/3 | Completed | Drug: AXS-05, Bupropion, Placebo | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor | 366 | 2017-07-13 | 2020-04-17actual | — | 2023-09-13 |
| CGTX | Cognition Therapeutics | $93M | Effect of CT1812 Treatment on Brain Synaptic DensityNCT03493282results2023-03-01Number of TEAEs, Related TEAEs, SAEs, and Related SAEs | Phase 1/2 | Completed | Drug: Active Treatment- CT1812 100 mg, Active Treatment- CT1812 300 mg, Placebo | Alzheimer Disease | 43 | 2018-03-28 | 2020-10-16actual | — | 2023-09-07 |
| HLUN-B.CO | H. Lundbeck A/S | — | Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's DiseaseNCT04149860Number of Participants with Treatment Emergent Adverse Events | Phase 1 | Completed | Drug: Lu AF87908, Placebo | Healthy, Alzheimer Disease | 86 | 2019-09-27 | 2023-07-19actual | — | 2023-08-04 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Alzheimer's Disease is matched — 17 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Alzheimer's Disease
- Alzheimer Disease
- Agitation in Patients With Dementia of the Alzheimer's Type
- Early Alzheimer's Disease
- Alzheimer Disease, Early Onset
- Alzheimers Disease
- Alzheimer's Disease Psychosis
- Alzheimer's Type Dementia
- Alzheimer´s Disease
- Dementia of Alzheimer Type
- Mild Alzheimer's Disease
- Agitation and Aggression in Alzheimer's Disease
- Alzheimer's Disease (AD)
- Alzheimer's Disease Dementia
- Dementia Alzheimer's Type
- Mild to Moderate Alzheimer's Disease
- Psychosis Associated With Alzheimer's Disease
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Alzheimer's Disease” (a text search, wider than this page)